Peer-reviewed veterinary case report
Oral fruit extract reduces mast cells in dogs with atopic dermatitis
By Shin, Ha-Young et al.·Published in Frontiers in veterinary science·2025·Korea Institute of Toxicology, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Oral treatment withfructus extract modulates mast cells in canine atopic dermatitis.
- Species:
- dog
Plain-English summary
A group of beagles with atopic dermatitis (a skin condition causing itching and inflammation) were treated with an oral fruit extract for two weeks to see if it could help their symptoms. The treatment led to noticeable improvements in their skin condition, reducing inflammation and the number of mast cells, which are involved in allergic reactions. The dogs showed less itching and irritation, and the treatment appeared to help balance their immune response. Overall, the fruit extract was effective in managing the symptoms of atopic dermatitis in these dogs.
People also search for: dog itching treatment · beagle skin problems · fruit extract for dog allergies
Abstract
INTRODUCTION: Canine atopic dermatitis is a hereditary, often pruritic, and predominantly T-cell-driven inflammatory skin disease involving an interplay between skin barrier abnormalities and allergen sensitization. However, progress in developing therapeutics for companion animals remains slow, with few drugs advancing to Phase II clinical trials to investigate the underlying mechanisms in target animals. Whilefruit extract (RMFE) has been strongly implicated in the improvement of various inflammatory diseases, its effects on canine atopic dermatitis (cAD) and the putative underlying mechanisms remain unclear. In this study, we aimed to evaluate the efficacy of RMFE in the treatment of cAD and explore its underlying mechanisms. METHODS: In this study, RMFE was administered orally (repeatedly for 2 weeks) to ovalbumin (OVA)-induced atopic dermatitis-induced beagles. The effects of RMFE on cAD were assessed through clinical symptom observation and scoring using the canine atopic dermatitis extent and severity index. Additionally, histopathological analysis was performed (hematoxylin and eosin, Masson's trichrome, and toluidine blue). Cluster of differentiation 4-positive immunostaining was also performed, along with cytokine level and messenger ribonucleic acid level analyses of T-helper 2 (Th2) immune and inflammatory response markers in the modeled skin. RESULTS: RMFE improved the clinical manifestations of cAD, leading to histopathological modulation of inflammation and immune cells. It also altered Th2 effector cytokine levels. Furthermore, RMFE reduced allergic responses in the AD model dogs by reducing mast cell numbers, inhibiting their activation to release inflammatory mediators, and reducing immunoglobulin E (IgE) production. DISCUSSION: Our results suggest that RMFE can modulate mast cell activation and Th2-dominant immune responses in cAD, helping to reduce AD-induced inflammatory responses.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40271492/